Peripheral Nerve Injury Market Size (7MM) was ~USD 2.4 Billion in 2023 and it is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Peripheral Nerve Injury Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Peripheral Nerve Injury, historical and forecasted epidemiology, and Peripheral Nerve Injury trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Discover which therapies are expected to grab the Peripheral Nerve Injury Market Share @ Peripheral Nerve Injury Market Outlook- https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Facts and Analysis of the Peripheral Nerve Injury Report
• In September 2025, Tissium, a Paris-based company, received FDA De Novo clearance for its non-traumatic peripheral nerve repair platform, enabling commercialization of its first product-a blue light-activated, biocompatible polymer shown to restore full finger movement without pain in clinical trials.
• In the 7MM, the US accounted for the highest number of cases of Peripheral Nerve Injuries, with nearly 1.7 million in 2023.
• Among EU4 and the UK, Italy accounted for the highest number of cases of Peripheral Nerve Injuries, followed by France, whereas Spain occupied the bottom of the ladder.
• The number of Upper extremities injuries are higher than that of Lower extremities injuries. In the US, in 2023, the former accounted for nearly 1.2 million, while the latter accounted for nearly 0.5 million.
• In the 7MM, the US accounted for the highest number surgeries Peripheral Nerve Injuries, with nearly 770 thousand in 2023.
• Key companies in the PNI market include Neuraptive Therapeutics Inc., Axogen Corporation, Integra Life Sciences Corporation, GlaxoSmithKline, Samyang Biopharmaceuticals Corporation, Astellas Pharma Inc., Bioness Inc., Epineuron Technologies Inc., Abbott, Glenmark Pharmaceuticals, SPR Therapeutics Inc., Pfizer, and others.
• Emerging drugs and devices in the PNI market include NTX-001, SilkBridge, CelGro, ONO-2910, and others.

Stay ahead in the Peripheral Nerve Injury Therapeutics Market with DelveInsight's Strategic Report @ Peripheral Nerve Injury Treatment Market- https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Nerve Injury Overview
Peripheral nerve injuries (PNIs) are complex conditions that involve damage to the nerves outside the brain and spinal cord, leading to disruptions in sensation, movement, and organ function. These injuries can arise from various causes, including traumatic events such as motor vehicle accidents, falls, sports-related injuries, or penetrating wounds. Additionally, conditions like carpal tunnel syndrome, nerve entrapment syndromes, and systemic diseases such as diabetes or autoimmune disorders can lead to PNIs. Symptoms of PNIs vary depending on the type and location of the affected nerves. Sensory nerve damage often manifests as pain, tingling, numbness, or altered sensations in the affected area, while motor nerve injuries may result in muscle weakness, paralysis, or muscle atrophy, impacting coordination and strength. As the number of peripheral nerve injuries patients increases, the demand for effective treatments in the peripheral nerve injuries market continues to grow.

Peripheral Nerve Injury Epidemiology
The Peripheral Nerve Injuries epidemiology chapter in the report offers both historical and forecasted data on the incidence of peripheral nerve injuries, segmented by annual PNI cases, the number of injuries by extremities, and the total number of PNI surgeries performed across the 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, from 2020 to 2034. In 2023, the US recorded the highest number of Peripheral Nerve Injuries cases, with nearly 1.7 million patients, reflecting the significant burden of PNI within the population. This comprehensive analysis provides insights into the evolving trends in PNI epidemiology and highlights the growing demand for targeted interventions for Peripheral Nerve Injuries patients.
• Annual cases of peripheral nerve injuries
• Annual number of peripheral nerve injuries by extremities
• Total number of PNI surgeries performed

Download the report to understand which factors are driving Peripheral Nerve Injury Epidemiology trends @ Peripheral Nerve Injury Prevalence- https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Nerve Injuries Marketed Products
• Avance Nerve Graft: Axogen Corporation
Avance Nerve Graft is an off-the-shelf processed human nerve allograft intended for the surgical repair of peripheral nerve discontinuities. Through a proprietary cleansing process for recovered human peripheral nerve tissue, the graft preserves the essential inherent structure of the extracellular matrix (ECM) while cleansing away cellular and noncellular debris. It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. It is processed and distributed by the US FDA and EU requirements for Human Cellular and Tissue-based Products. It had also received Regenerative Medicine Advanced Therapy (RMAT) Designation in 2018, and the company is also conducting a phase III clinical trial, ECON Study, to support its Biologic License Application (BLA) Submission. With the final subject enrolled in July 2020, the last patient is expected to complete the study no later than October of 2021. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

• Nerbridge: Toyobo
Nerbridge is a resorbable, artificial nerve conduit with polyglycolic acid tubing and a collagenous interior. It is the only such device currently approved in Japan. Nerbridge is mainly used in clinical practice to bridge peripheral nerves after traumatic nerve injury, but there are few reports on its application in reconstruction and repair of the facial nerve. In a study, the utility of Nerbridge to promote nerve regeneration has been evaluated in a murine model of injury to the buccal branch of the facial nerve. The use of Nerbridge has been reported mainly in orthopedic surgery, and its efficacy in trials was 82.8%. The ccompany reports two cases of lingual nerve reconstruction using Nerbridge. In both cases, the lingual nerve was resected due to submandibular gland cancer. The company evaluated the cases by the Semmes-Weinstein monofilaments test. There are problems with length restriction and price, but it is one of the effective reconstruction methods for the reconstruction of the lingual nerve.

Emerging Peripheral Nerve Injuries Drugs/Devices
• NTX-001: Neuraptive Therapeutics
NTX-001 is a kit used during surgical nerve repairs after trauma or during face and body reconstructive procedures. It is (comprised of previously approved components) provided as sterile solutions. The active pharmaceutical agent is a topically administered product used in conjunction with a delivery device directly to the nerve. The therapy has been extensively studied in preclinical studies, and early clinical cases support advancing into the mid-stage clinical studies. NTX-001 is a potentially transformative adjunctive treatment for peripheral nerve injuries, using a propriety system for the reconnection of severed nerves. Neuraptive Therapeutics is also investigating other therapies for nerve repair. NTX-002 is a device that is under investigation in the preclinical phase as a nerve repair device.

• SilkBridge: KLISBio
SilkBridge consists of a silk fibroin (SF) scaffold with a hybrid electrospun-textile structure in which electrospun (ES) layers, in the inner and outer parts of the device, are coupled to the textile (TEX) layer, in the middle. This configuration allows the body's natural healing process to repair the nerve while its tube shape isolates and protects the injured nerves during the healing process. Silk fibroin is fully biocompatible and promotes cell proliferation by stimulating in vivo tissue regeneration. SilkBridge has an optimized balance of biomechanical and biological properties, can sustain perfect cellular colonization of the conduit and the progressive growth of the regenerating nerve fibers.

• CelGro: Orthocell Limited
CelGro is a unique collagen medical device intended for use in tissue regeneration and repair. CelGro enhances nerve regeneration in 3 different ways.

To learn more about Peripheral Nerve Injuries Treatment guidelines, visit @ Peripheral Nerve Injuries Clinical Trials Assessment- https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Nerve Injury Therapies and Companies
• NTX-001: Neuraptive Therapeutics
• SilkBridge: KLISBio
• CelGro: Orthocell Limited
• ONO-2910: Ono Pharmaceutical

Peripheral Nerve Injury Market Outlook
Peripheral nerve injuries can cause significant discomfort and affect muscle innervation or lead to a loss of sensation. These injuries can occur in individuals of all ages and result from various causes, including medical conditions or trauma. PNIs most commonly affect the upper limbs and are often linked to traumatic events, presenting symptoms such as paraesthesia, weakness, paralysis, and pain. Severe nerve damage often requires surgical intervention, with treatment strategies tailored to the type of injury. The primary goal of treatment is to restore sensory, motor, and autonomic functions by promoting axon regeneration. However, existing therapies and Peripheral Nerve Injuries drugs may not always ensure full recovery. As the Nerve Injuries market grows, there is a heightened focus on developing innovative Peripheral Nerve Injuries therapies to improve outcomes for patients.

Peripheral Nerve Injury Treatment Market
Treatment strategies for peripheral nerve injuries (PNIs) focus on alleviating symptoms, promoting nerve healing, and restoring function. In mild cases, conservative management typically involves rest, activity modification, physical therapy, and pain management with medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or neuropathic pain medications. Orthotic devices, splints, or braces may also be used to support and protect the affected limbs. For more severe cases, surgical intervention is often necessary to repair nerve damage and restore sensory, motor, and autonomic function. In recent developments of Peripheral Nerve Injury Treatment Market, Neuraptive Therapeutics' NTX-001 received Breakthrough Therapy Designation in September 2024, facilitating its accelerated development for PNI repair. Additionally, NTX-001 received Orphan Drug Designation in January 2024, and was granted Fast Track Designation in May 2020. As the Peripheral Nerve Injuries market expands, ongoing advancements in therapies and drugs offer promising solutions for improved patient outcomes.

Learn more about the FDA-approved drugs for Peripheral Nerve Injury @ Drugs for Peripheral Nerve Injury Treatment- https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral Nerve Injury Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Peripheral Nerve Injury Companies: Neuraptive Therapeutics Inc., Axogen Corporation, Integra Life Sciences Corporation, GlaxoSmithKline, Samyang Biopharmaceuticals Corporation, Astellas Pharma Inc., Bioness Inc., Epineuron Technologies Inc., Abbott, Glenmark Pharmaceuticals, SPR Therapeutics Inc., Pfizer, and others.
• Peripheral Nerve Injury Therapies: NTX-001, SilkBridge, CelGro, ONO-2910, and others.
• Peripheral Nerve Injury Therapeutic Assessment: Peripheral Nerve Injury current marketed and Peripheral Nerve Injury emerging therapies
• Peripheral Nerve Injury Dynamics: Peripheral Nerve Injury drivers and Peripheral Nerve Injury barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Peripheral Nerve Injury Unmet Needs, KOL's views, Analyst's views, Peripheral Nerve Injury Access and Reimbursement

Table of Contents
1. Peripheral Nerve Injury Report Introduction
2. Executive Summary for Peripheral Nerve Injury
3. SWOT analysis of Peripheral Nerve Injury
4. Peripheral Nerve Injury Patient Share (%) Overview at a Glance
5. Peripheral Nerve Injury Overview at a Glance
6. Peripheral Nerve Injury Disease Background and Overview
7. Peripheral Nerve Injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Peripheral Nerve Injury
9. Peripheral Nerve Injury Current Treatment and Medical Practices
10. Peripheral Nerve Injury Unmet Needs
11. Peripheral Nerve Injury Emerging Therapies
12. Peripheral Nerve Injury Outlook
13. Country-Wise Peripheral Nerve Injury Analysis (2020-2034)
14. Peripheral Nerve Injury Access and Reimbursement of Therapies
15. Peripheral Nerve Injury Drivers
16. Peripheral Nerve Injury Barriers
17. Peripheral Nerve Injury Appendix
18. Peripheral Nerve Injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.